The 212A Variant of the APJ Receptor Gene for the Endogenous Inotrope Apelin is Associated With Slower Heart Failure Progression in Idiopathic Dilated Cardiomyopathy

Journal of Cardiac Failure

Volumn 13, Issue 7, 2007, Pages 521-529

  Sarzani, Riccardo ^a   Forleo, Cinzia ^b   Pietrucci, Francesca ^a   Capestro, Alessandro ^a   Soura, Elli ^a   Guida, Pietro ^b   Sorrentino, Sandro ^b   Iacoviello, Massimo ^b   Romito, Roberta ^b   Dessì Fulgheri, Paolo ^a   Pitzalis, Mariavittoria ^c   Rappelli, Alessandro ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c EAST CAROLINA UNIVERSITY   (United States)

Author keywords

apelin; APJ; cardiomyopathy

Indexed keywords

ADENINE; APELIN; INOTROPIC AGENT; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; APJ RECEPTOR GENE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HOMOZYGOTE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; UNIVARIATE ANALYSIS; UNTRANSLATED REGION;

ADENINE; ADULT; ALLELES; CARDIOMYOPATHY, DILATED; CYTOSINE; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENE DOSAGE; GENOTYPE; GUANINE; HAPLOTYPES; HOMOZYGOTE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, G-PROTEIN-COUPLED; VARIATION (GENETICS);

EID: 34548409543     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.04.002     Document Type: Article

References (31)

1. O'Dowd B.F., Heiber M., Chan A., Heng H.H.Q., Tsui L.C., Kennedy J.L., et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136 (1993) 355-360
2. Tatemoto K., Hosoya M., Habata Y., Fujii R., Kakegawa T., Zou M.X., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251 (1998) 471-476
3. Lee D.K., Cheng R., Nguyen T., Fan T., Kariyawasam A.P., Liu Y., et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 74 (2000) 34-41
4. Reaux A., De Mota N., Skultetyova L.Z.L., El Messari S., Gallatz K., Corvol P., et al. Physiological role of a novel neuropeptide, apelin and its receptor in the rat brain. J Neurol 77 (2001) 1085-1096
5. Reaux A., Gallatz K., Palkovits M., and Llorens-Cortes C. Distribution of apelin-synthesizing neurons in the adult rat brain. Neuroscience 13 (2002) 653-662
6. Medhurst A.D., Jennings C.A., Robbins M.J., Davis R.P., Ellis C., Winborn K.Y., et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 84 (2003) 1162-1172
7. Hosoya M., Kawamata Y., Fukusumi S., Fujii R., Habata Y., Hinuma S., et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 275 (2000) 21061-21067
8. 125I] - (Pyr)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 132 (2001) 1255-1260
9. Kawamata Y., Habata Y., Fukusumi S., Hosoya M., Fujii R., Hinuma S., et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 1538 (2001) 162-171
10. Katugampola S.D., Kuc R.E., Maguire J.J., and Davemport A.P. G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. Clin Sci 103 Suppl 48 (2002) 171S-175S
11. Katugampola S.D., Maguire J.J., Kuc R.E., Wiley K.E., and Devemport A.P. Discovery of recently adopted orphan receptor for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. Can J Physiol Pharmacol 80 (2002) 369-374
12. Chen M.M., Ashley E.A., Deng D.X.F., Tsalenko A., Deng A., Tabibiazar R., et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108 (2003) 1432-1439
13. Tatemoto K., Takayama K., Zou M.X., Kumaki I., Zhang W., Kumano K., et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 99 (2001) 87-92
14. Seyedabadi M., Goodchild A.K., and Pilowsky P.M. Site-specific effects of apelin-13 in the rat medulla oblongata on arterial pressure and respiration. Auton Neurosci 101 (2002) 32-38
15. Berry M.F., Pirolli T.J., Jayasankar V., Burdick J., Morine K.J., Gardner T.J., et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 110 (2004) II187-II193
16. Ishida J., Hashimoto Y., Nishiwaki S., Iguchi T., Harada S., Sugaya T., et al. Regulatory roles of APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 279 (2004) 26274-26279
17. Szokodi I., Tavi P., Foldes G., Voutilainen-Myllyla S., Ilves M., Tokola H., et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 91 (2002) 434-440
18. Foldes G., Horkay F., Szokodi I., Vuolteenaho O., Ilves M., Lindstedt K.A., et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 308 (2003) 480-485
19. Kleinz M.J., Skepper J.N., and Davenport A.P. Immunocytochemical localisation of the apeli receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 126 (2005) 233-240
20. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93 (1996) 841-842
21. Forleo C., Resta N., Sorrentino S., Guida P., Manghisi A., De Luca V., et al. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 117 (2004) 451-458
22. Tiret L., Mallet C., Poirier O., Nicaud V., Millaire A., Bouhour J.B., et al. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J Am Coll Cardiol 35 (2000) 29-35
23. Colucci W.S., Packer M., Bristow M.R., Gilbert E.M., Cohn J.N., Fowler M.B., et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 94 (1996) 2800-2806
24. Narang R., Cleland J.G., Erhardt L., Ball S.G., Coats A.J., Cowley A.J., et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 17 (1996) 1390-1403
25. Terwilliger J., and Ott J. Handbook of human genetic linkage (1994), Johns Hopkins University Press, Baltimore, MD
26. Seidman J.G., and Seidman C. The genetic basis of cardiomyopathy: from mutations identification to mechanistic paradigms. Cell 104 (2001) 557-567
27. Lee D.K., George S.R., and O'Dowd B. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 4 (2006) 190-194
28. Chong K.S., Gardner R.S., Morton J.J., Ashley E.A., and McDonagh T.A. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 8 (2006) 355-360
29. Francia P., Salvati A., Balla C., De Paolis P., Pagannone E., Borro M., et al. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail 9 (2007) 306-309
30. Jia Y.X., Pan C.S., Zhang J., Geng B., Zhao J., Gerns H., et al. Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept 133 (2006) 147-154
31. Ashley E.A., Powers J., Chen M., Kundu R., Finsterbach T., Caffarelli A., et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 65 (2005) 73-82